chloroquine has been researched along with Cardiac Toxicity in 16 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the effect of LE on chloroquine (CQ)-evoked cardiac toxicity remains unclear." | 8.31 | Lipid emulsion inhibits the cardiac toxicity caused by chloroquine via inhibition of reactive oxygen species production. ( Ahn, SH; Kim, HJ; Kim, M; Lee, SH; Ok, SH; Sim, G; Sohn, JT; Yoon, S, 2023) |
| " Although, most adverse cardiac events related to HCQ/CQ usage in COVID-19 were secondary to conduction disorders given the short duration of treatment, HCQ/CQ can cause CM and HF, with chronic usage." | 6.82 | Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. ( Gagnon, LR; Oudit, GY; Sadasivan, C; Yogasundaram, H, 2022) |
| " The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart." | 5.91 | Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress. ( Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023) |
| " However, the effect of LE on chloroquine (CQ)-evoked cardiac toxicity remains unclear." | 4.31 | Lipid emulsion inhibits the cardiac toxicity caused by chloroquine via inhibition of reactive oxygen species production. ( Ahn, SH; Kim, HJ; Kim, M; Lee, SH; Ok, SH; Sim, G; Sohn, JT; Yoon, S, 2023) |
| "Neither diazepam nor other ligands for benzodiazepine binding sites protect against or attenuate chloroquine cardiotoxicity." | 3.96 | Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam. ( Hughes, DA, 2020) |
| "Cardiotoxicity is a well-known side effect of chloroquine." | 3.91 | Revisiting the Cardiotoxic Effect of Chloroquine. ( Blignaut, M; Dhanabalan, K; Espach, Y; Huisamen, B; van Vuuren, M, 2019) |
| " Although, most adverse cardiac events related to HCQ/CQ usage in COVID-19 were secondary to conduction disorders given the short duration of treatment, HCQ/CQ can cause CM and HF, with chronic usage." | 2.82 | Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. ( Gagnon, LR; Oudit, GY; Sadasivan, C; Yogasundaram, H, 2022) |
| " However, some of these medications have potential cardiac adverse effects." | 2.66 | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020) |
| " The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart." | 1.91 | Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress. ( Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023) |
| " Awareness of the potential adverse cardiac effects of HCQ and CQ can increase the safe use of these medications." | 1.62 | American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. ( Costenbader, KH; Desmarais, J; Fett, N; Ginzler, EM; Goodman, S; Kovacs, R; Link, MS; O'Dell, J; Pineau, CA; Rosenbaum, JT; Schmajuk, G; Werth, VP, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 14 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Desmarais, J | 1 |
| Rosenbaum, JT | 1 |
| Costenbader, KH | 1 |
| Ginzler, EM | 1 |
| Fett, N | 1 |
| Goodman, S | 1 |
| O'Dell, J | 1 |
| Pineau, CA | 1 |
| Schmajuk, G | 1 |
| Werth, VP | 1 |
| Link, MS | 1 |
| Kovacs, R | 1 |
| Gagnon, LR | 1 |
| Sadasivan, C | 1 |
| Yogasundaram, H | 1 |
| Oudit, GY | 1 |
| Lee, SH | 1 |
| Ok, SH | 1 |
| Ahn, SH | 1 |
| Sim, G | 1 |
| Kim, HJ | 1 |
| Kim, M | 1 |
| Yoon, S | 1 |
| Sohn, JT | 1 |
| Seydi, E | 1 |
| Hassani, MK | 1 |
| Naderpour, S | 1 |
| Arjmand, A | 1 |
| Pourahmad, J | 1 |
| Abdelmageed, N | 1 |
| Twafik, WA | 1 |
| Morad, OA | 1 |
| Haridy, M | 1 |
| Hassan, R | 1 |
| Ahmed, M | 1 |
| El-Zorba, HY | 1 |
| El-Banna, HA | 1 |
| Seddek, AL | 1 |
| Ghallab, A | 1 |
| Morad, SAF | 1 |
| Hanneman, K | 1 |
| Alberdi, HV | 1 |
| Karur, GR | 1 |
| Tselios, K | 1 |
| Harvey, PJ | 1 |
| Gladman, DD | 1 |
| Akhtari, S | 1 |
| Osuntokun, T | 1 |
| Wald, RM | 1 |
| Thavendiranathan, P | 1 |
| Butany, J | 1 |
| Urowitz, MB | 1 |
| Bauman, JL | 1 |
| Tisdale, JE | 1 |
| Lentini, G | 1 |
| Cavalluzzi, MM | 1 |
| Habtemariam, S | 1 |
| Monzani, A | 1 |
| Genoni, G | 1 |
| Scopinaro, A | 1 |
| Pistis, G | 1 |
| Kozel, D | 1 |
| Secco, GG | 1 |
| Naksuk, N | 1 |
| Lazar, S | 1 |
| Peeraphatdit, TB | 1 |
| Hughes, DA | 1 |
| Kamp, TJ | 1 |
| Hamdan, MH | 1 |
| January, CT | 1 |
| Kim, YS | 1 |
| Lee, SY | 1 |
| Yoon, JW | 1 |
| Kim, D | 1 |
| Yu, S | 1 |
| Kim, JS | 1 |
| Kim, JH | 1 |
| Jordaan, P | 1 |
| Dumotier, B | 1 |
| Traebert, M | 1 |
| Miller, PE | 1 |
| Ghetti, A | 1 |
| Urban, L | 1 |
| Abi-Gerges, N | 1 |
| Chatre, C | 1 |
| Roubille, F | 1 |
| Vernhet, H | 1 |
| Jorgensen, C | 1 |
| Pers, YM | 1 |
| Blignaut, M | 1 |
| Espach, Y | 1 |
| van Vuuren, M | 1 |
| Dhanabalan, K | 1 |
| Huisamen, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for chloroquine and Cardiac Toxicity
| Article | Year |
|---|---|
Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Heart Failure; Humans; Hydroxychloroquine; Pan | 2022 |
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; | 2020 |
Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
Topics: Betacoronavirus; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Global Health; Heart | 2020 |
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.
Topics: Antimalarials; Cardiotoxicity; Chloroquine; Dose-Response Relationship, Drug; Female; Heart Diseases | 2018 |
12 other studies available for chloroquine and Cardiac Toxicity
| Article | Year |
|---|---|
American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Topics: Antimalarials; Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine | 2021 |
Lipid emulsion inhibits the cardiac toxicity caused by chloroquine via inhibition of reactive oxygen species production.
Topics: Adenosine Triphosphate; Animals; Calcium; Cardiotoxicity; Chloroquine; Emulsions; Rats; Reactive Oxy | 2023 |
Cardiotoxicity of chloroquine and hydroxychloroquine through mitochondrial pathway.
Topics: Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochromes c; Humans; Hydroxychloro | 2023 |
Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress.
Topics: Animals; Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hydroxychloroquine; Mice; O | 2023 |
Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI.
Topics: Adult; Aged; Antimalarials; Biopsy; Cardiomyopathies; Cardiotoxicity; Chloroquine; Diagnosis, Differ | 2020 |
Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Risk Factors; SARS | 2020 |
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
Topics: Antimalarials; Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Cardiotoxicity; Chloroquine; | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infec | 2020 |
Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam.
Topics: Animals; Arrhythmias, Cardiac; Benzodiazepinones; Cardiotoxicity; Chloroquine; Clonazepam; Coronavir | 2020 |
Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Cell Differentiation | 2020 |
Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Cardiotoxicity; Chloroquine; COVID-1 | 2021 |
Revisiting the Cardiotoxic Effect of Chloroquine.
Topics: Animals; Antimalarials; Cardiotoxicity; Cell Survival; Chloroquine; Dose-Response Relationship, Drug | 2019 |